A multi-asset strategy single family office is involved in real estate management and venture investments. The group has offices in US and China, and the firm’s venture investment arm seeks to invest in early-stage, innovative technology companies. The firm typically engages in seed to series A rounds and prefers life science and healthcare companies with high-tech components. The initial check size from $100K-1M USD. The firm is interested in companies based in the US.
The firm possesses extensive expertise in cross border investments and collaboration. The firm can leverage its local networks and resources if their portfolio companies have the willingness to expand their businesses in China on various fronts, such as securing additional funding. Because of this unique strategic advantage, the firm maintains a special interest in companies with a China angle and firms with products or technologies suited for the Chinese market.
While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.
The firm seeks life science and healthcare companies that incorporate high-tech components, such as AI in healthcare and life sciences. The firm is open to considering medical devices, and digital health, and its opportunistic regarding subsectors and indications. Due to the scientific background of its team, the firm is particularly interested in chronic diseases such as diabetes and cardiovascular diseases.
There are no specific requirements for the company and the management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment